April 28th 2024
During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Standard Therapy Selection for Cholangiocarcinoma Needs Further Interpretation
April 17th 2019Besides standard-of-care chemotherapy in the frontline setting, definitive therapy selection in patients with cholangiocarcinoma in both the adjuvant and second-line settings require data from confirmatory clinical trials for further clarification, says Lorenza Rimassa, MD.
Read More
Patient Misconceptions About Clinical Trials Are a Common Source of Resistance, Expert Panel Says
April 8th 2019Before a community oncology practice considers getting involved in clinical trials research, there are many factorsto consider. Perhaps foremost is the fact that cancer clinical trials provide the evidence base for new advances in oncology.
Read More
Despite Slow Adoption, Artificial Intelligence Pilot Programs Yield Practical Results
April 6th 2019Artificial intelligence has made inroads in many industries—banking, finance, security—but its adoption in healthcare has been lagging and real-world clinical implementation has yet to become a reality. Nonetheless, proponents say it is only a matter of time and pilot programs are starting to yield some practical results.
Read More
Challenges Persist With CAR T-Cell Therapy in Pancreatic Cancer
April 2nd 2019The success of chimeric antigen receptor T-cell therapy observed in hematologic malignancies has not yet translated into the solid tumor setting; however, efforts continue to try to bring this new modality into the treatment paradigm for solid tumors, including pancreatic cancer.
Read More
NGS Testing of HCC Reveals Potential Biomarkers and Mutations for Treatment Matching
March 29th 2019An analysis of the genotyping of tumor tissue samples from patients with hepatocellular carcinoma identified frequent alterations and potentially actionable mutations in cases of HCC, and helped to confirm the clinical utility of next-generation sequencing testing for matching patients to targeted therapies and immunotherapies.
Read More
CMS Mulls Opposition to Downsizing Part D Protected Drug Classes
March 15th 2019The healthcare community is still awaiting a response from the Centers for Medicare & Medicaid Services to the opposition of the agency’s proposal to substantially revise the Medicare Part D protected drug classes.
Read More
Avoiding Overtreatment Saves Medicare $320M Over 3-Year Period in Older Men With Prostate Cancer
March 13th 2019Overtreating men 70 years or older with prostate cancer cost Medicare more than $1.2 billion from 2004 to 2007, according to the results of a retrospective study using the Surveillance, Epidemiology, and End Results–Medicare linked database.
Read More
Expert Considers First- and Second-Line Treatment Options in Case Studies of Patients With HCC
March 1st 2019During a <em>Targeted Oncology </em>live case-based peer perspectives program, Ruth He, MD, PhD, discussed her strategies for treating patients with liver cancer as more therapeutic options enter the landscape.
Read More
Expert Highlights Impact of Lenvatinib in Frontline HCC
February 25th 2019Masatoshi Kudo, MD, PhD, discusses the results from the REFLECT trial and an analysis presented at the 2019 Gastrointestinal Cancers Symposium, as well as other research currently ongoing for this patient population.
Read More
Pembrolizumab Falls Short in Confirmatory HCC Trial
February 21st 2019Merck, the developer of pembrolizumab, has announced that the coprimary endpoints of the KEYNOTE-240 trial were not met, as adding the agent to best supportive care failed to improve progression-free or overall survival in patients with advanced hepatocellular carcinoma who were previously treated with systemic therapy.
Read More
Rare Incidence of ICI-Related Hepatotoxicity Frequently Ends in Treatment Discontinuation
February 12th 2019Although immune checkpoint inhibition–related hepatotoxicity is a rare occurrence, it leads to ICI treatment discontinuation in more than two-thirds of affected patients, according to the results of a retrospective study presented at the American Association for the Study of Liver Diseases’ 2018 Liver Meeting.
Read More
Regorafenib Brings Positive Response Following Liver Transplantation
February 7th 2019Using regorafenib after hepatocellular carcinoma progression on sorafenib in the post–liver transplantation setting produced overall survival effects similar to those of patients without liver transplant, according to results presented at the American Association for the Study of Liver Diseases’ 2018 Liver Meeting.
Read More
Search Continues for a Refined Sorafenib Combo in HCC
January 28th 2019The combination of sorafenib and modified FOLFOX demonstrated encouraging efficacy in a small phase II study, but some patients exhibited moderate hepatoxicity, according to investigators from the Massachusetts General Hospital Cancer Center.
Read More